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Second Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago 683-
0826, Japan
We report a patient with a rare association of chronic fatigue syndrome (CFS) and IgA
nephropathy (IgAN).  The patient was a  45-year-old woman who presented initially
with biopsy proven IgAN and 2 years later developed CFS.  Because of proteinuria and
hematuria, she was referred to our clinic.  A renal biopsy done at that time revealed
IgAN.  Then she was struck by the sudden onset of profound fatigue.  According to
criteria published by the Centers for Disease Control and Prevention in the United
States, we diagnosed her illness as CFS.
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Chronic fatigue syndrome (CFS) is character-
ized by a principal complaint of severe fatigue
of at least 6 month’s duration.  No single patho-
genic mechanism has been consistently identi-
fied using physical or laboratory tests, thus
making the diagnosis of CFS one of exclusion
(DeLuca et al., 1997; Komaroff et al., 1997).
We report a patient with a rare association of
CFS and IgA nephropathy (IgAN).
Patient Report
In August 1994, a 43-year-old woman was re-
ferred to our hospital because of episodes of
proteinuria and occult hematuria.  She was a
housewife and a sales representative of the de-
partment store.  A renal biopsy done at this time
revealed IgAN to a moderate degree.  Micro-
scopic examination of her renal biopsy tissues
showed a focal segmental proliferative glomer-
ulonephritis (Fig. 1).  Mesangial granular de-
posits of IgA and C3 were identified by immuno-
fluorescence.
During the follow-up where she was given a
75 mg daily dose of dipyridamole she remained
Abbreviations:  CDC, United States Centers for Dis-
ease Control and Prevention; CFS, chronic fatigue
syndrome; IgAN, IgA nephropathy; IU, Internation-
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well, in a rather good condition, except for per-
sistent microhematuria and proteinuria.  In May
1995 she developed the sudden onset of pro-
found fatigue, morning stiffness and low grade
fever without any clear precipitating factor.
Since that time, she has felt extraordinary weak-
ness, finding herself unable to go to work.  She
could not even go about household chores.  The
exhaustion forces her to spend many hours in
bed.  Because of increasing severe myalgia and
arthralgia, she was admitted to our hospital for
the second time in November 1996.
On admission, her weight was 62.8 kg and
her height was 150.2 cm.  Her lower extremities
were slightly edematous.  Blood pressure was
150/72 mm Hg.  Abnormal laboratory findings
were:  urinary protein 2+, occult hematuria 2+,
urinary protein excertion 2.6 g/day, white blood
cell count 21700/ m L, blood urea nitrogen 43
mg/dL, serum creatinine 2.0 mg/dL, uric acid
9.7 mg/dL, total protein 5.0 g/dL, albumin 3.1
g/dL and b 2-microglobulin 2.85 mg/L.  Sero-
logical tests for rheumatoid factor, antinuclear
and antineutrophil cytoplasmic antibodies, hepati-
tis B and C, Epstein-Barr virus and herpes simplex
virus were negative.  Serum IgA 188 mg/dL, acyl-
carnitine 15.4 m mol/L, creatine phosphokinase
30 IU/L and C-reactive protein 0.01 mg/dL lev-
els were within the normal range.
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All symptoms of the United States Centers
for Disease Control and Prevention (CDC) cri-
teria except lymph node swelling were satisfied
in this patient.  She complained of terrible mus-
cle pain and multi-joint pain, even when she
turned over in bed.  As a result of remarkable
muscle weakness, she could not go up stairs.  At
the same time, atopic symptoms flared up on
her skin.  A muscle biopsy on the biceps muscle
of her arm was performed to exclude the
possibility of polymyositis or dermatomyositis
(Fig. 2).  But her biopsy tissues did not show
any abnormal findings.
Until now no controlled studies have pro-
vided convincing evidence of the efficacy of
any treatment for CFS.  However, a recent re-
port revealed that circulating levels of cortisol
in patients with CFS were relatively low
(Mckenzie et al., 1998; Scott et al., 1998).  To
evaluate the efficacy of oral hydrocortisone as a
treatment for CFS, a 30 mg daily dose of pred-
nisolone was initiated.  Severe fatigue, myalgia
and fever were not improved.  Then we tried
Chinese herbal medicine (Hochuekkito) and a
nonsteroidal anti-inflammatory drug (sulindac).
After administration of these drugs her myalgia,
arthralgia and even severe fatigue were
remarkably reduced.  She was discharged in
May 1997.
Discussion
In 1988, the CDC proposed the term “chronic
fatigue syndrome” and a definition for diagno-
sis.  This definition was refined in 1994 by the
International CFS Study Group (Nishikai,
1996).  The revised CFS classification criteria
requires
a) severe fatigue persisting for more than 6
months,
b) chronic fatigue of a new or definite onset,
not the result of ongoing exertion, not sub-
stantially relieved by rest and resulting in a
substantial reduction in previous levels of
social or personal activities,
c) four or more of the following symptoms oc-
curring concurrently:  impairment of memo-
ry or concentration, sore throat, tender cervi-
cal or axillary lymph nodes, muscle pain,
headache, unrefreshing sleep and postexer-
tional malaise.
Fig. 1.  Renal biopsy sample, periodic acid-Schiff-stained section ( ·  200).
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This report is the first description of CFS
associated with IgAN.  Because immune-
mediated mechanisms may be a cause of IgAN
and CFS, we hypothesized that this association
might be linked with a common pathogenesis.
IgAN is the most common form of glomer-
ulonephritis, with a prevalence ranging from
10% of renal biopsies in the United States to
30–40% in Japan (Hemmen et al., 1997).  The
mean age range is generally in the second or
third decade.  Haematuria as the presenting
symptom is found in 80% and proteinuria in
71% of the patients.  In 40% of the patients with
IgAN, the progressive disease leads to end-
stage renal failure.  Recently, the role of the
monocyte system and IL6 secretion in the
pathogenesis and progression of IgAN has been
emphasized (Tsimaratos et al., 1996).  It has been
suggested that age-dependent variations in the
development of the IgAN mucosal system or in-
dividual differences in antigen exposure or
handling of immune complexes may play an
important role.  The prevalence of DQ4/8/9 and
DR4 is high among Japanese patients with
IgAN (Taniguchi et al., 1997).
Immunologic abnormalities are also report-
ed in CFS (Plioplys et al., 1997):  decreased
function in natural killer cells and macro-
phages; reduced mitogenic response of lympho-
cytes; B-cell subset changes, and activation of
CD8 cells.  There have also been reports of the
presence of circulating immune complexes, de-
creased complement, and the presence of anti-
cardiolipin and antiphospholipid antibodies.
However, the evidence for an immunological
basis for CFS is as tantalizingly non-specific as
is the evidence for a viral etiology (Dickinson,
1997).
The present patient  may provide further
immune-mediated mechanisms for IgAN and
CFS.
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